Neuroblastoma (NB) is the second most common solid pediatric tumor and is characterized by clinical and biological heterogeneity, and stage-IV of the disease represents 50% of all cases. Considering the limited success of present chemotherapy treatment, it has become necessary to find new and effective therapies. In this context, our approach consists of identifying and targeting key molecular pathways associated with NB chemoresistance. This study has been carried out on three stage-IV NB cell lines with different status of MYCN amplification. Cells were exposed to a standard chemotherapy agent, namely etoposide, either alone or in combination with particular drugs, which target intracellular signaling pathways. Etoposide alone induced a concentration-dependent reduction of cell viability and, at very high doses, totally counteracted cell tumorigenicity and neurosphere formation. In addition, etoposide activated p38 mitogen-activated protein kinase (MAPK), AKT and c-Jun N-terminal kinase. Pre-treatment with SB203580, a p38MAPK inhibitor, dramatically sensibilized NB cells to etoposide, strongly reducing the dosage needed to inhibit tumorigenicity and neurosphere formation. Importantly, SB203580-etoposide cotreatment also reduced cell migration and invasion by affecting cyclooxygenase-2, intercellular adhesion molecule-1, C-X-C chemokine receptor-4 and matrix metalloprotease-9. Collectively, our results suggest that p38MAPK inhibition, in combination with standard chemotherapy, could represent an effective strategy to counteract NB resistance in stage-IV patients. 1,2 While low-risk NB may spontaneously regress or differentiate into benign ganglioneuroblastoma, high-risk NB (stage-IV) results in metastatic dissemination 3 and only 20% of patients survive 5 years from diagnosis in spite of aggressive chemotherapy. 4 Current therapeutic stratification of patients with NB is based on risk assessment according to combinations of age, tumor stage, MYCN status, DNA ploidy status and histopathology. This biological heterogeneity renders it necessary to identify additional markers for stratification and prognostication, as well as molecular pathways that can be targeted in combination with standard chemotherapy. However, the efficacy of the single-agent therapy is limited by mechanisms of resistance that hinder its clinical success. A factor that contributes to the malignancy of NB is the presence of a subpopulation of chemo-and radio-resistant stem cells in the tumor bulk.
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Subject Category: Cancer Neuroblastoma (NB) is the second most common pediatric solid malignant tumor and is characterized by biological and clinical heterogeneity. 1, 2 While low-risk NB may spontaneously regress or differentiate into benign ganglioneuroblastoma, high-risk NB (stage-IV) results in metastatic dissemination 3 and only 20% of patients survive 5 years from diagnosis in spite of aggressive chemotherapy. 4 Current therapeutic stratification of patients with NB is based on risk assessment according to combinations of age, tumor stage, MYCN status, DNA ploidy status and histopathology. This biological heterogeneity renders it necessary to identify additional markers for stratification and prognostication, as well as molecular pathways that can be targeted in combination with standard chemotherapy. However, the efficacy of the single-agent therapy is limited by mechanisms of resistance that hinder its clinical success. A factor that contributes to the malignancy of NB is the presence of a subpopulation of chemo-and radio-resistant stem cells in the tumor bulk. 5 These cancer stem-like cells (CSCs) contribute to both cancer progression and metastases. In NB, in fact, neurospheres (NBSs), the CSCs of neuronal origin, have been found in primary tumor specimens, as well as in established cell lines. 6 Moreover, it has been demonstrated that therapy-resistant aggressive NBs frequently overexpress and secrete high levels of growth factors and chemokines, 7 which are able to activate growth signaling pathways, thereby providing a suitable microenvironment for tumor development. 8, 9 In this study, we analyzed the main survival and death pathways triggered by etoposide, a commonly used chemotherapeutic compound, in two MYCN-amplified and one non-amplified cell lines. In particular, our study was strongly focused on HTLA-230, one of the MYCN-amplified NB cell lines, isolated from the bone-marrow aspirate of a patient with the stage-IV disease. 10 These cells are highly tumorigenic 11 and phenotypically similar to other metastatic bone marrowisolated NB cells.
(MAPK) inhibitor, in combination with etoposide, may be effective in preventing cell growth, invasion, migration, angiogenesis and NBS generation, which are all factors responsible for the relapse and progression of NB.
Results
Etoposide induces a dose-dependent reduction of cell viability and high doses totally counteract the tumorigenicity of NB cells and the formation of NBSs. NB cells were exposed for 24 h to increasing concentrations of etoposide (0.07-225 mM). As shown in Figure 1a , etoposide induced a dose-dependent reduction of cell viability, starting at a 10 mM concentration and reaching a 70% decrease at 225 mM. As shown in Figure 1b (left panel), untreated cells were able to form colonies (68 colonies of 450 cells). Similarly, NB cells exposed for 24 h to 1.25 mM etoposide, a concentration that mimics in vitro the dose used in clinical therapy, 13 formed colonies (44 colonies of 450 cells). On the contrary, higher doses of etoposide (from 10 to 225 mM) totally suppressed the clonogenicity of these cells.
Since the anchorage-independent growth is useful in detecting colonies, not appreciated by a clonogenic assay, 14 cells treated for 24 h with etoposide were grown in a semisolid agar. Similarly, as shown in Figure 1b When cells were plated above the clonal density (10 cells per ml) and grown under appropriate conditions, many NBSs were observed within 1 week in both untreated and 1.25 mM etoposide-treated cells (Figure 1c) . Interestingly, the quantity of NBSs increased with the passage number (Figure 1c ), but higher doses of etoposide (10-100 mM) prevented the formation of NBSs, already during the first week ( Figure 1c) .
As shown in Figure 1d , untreated and etoposide-treated monolayer cells expressed CD133 and Oct4, known stem cell markers. 15 Moreover, in NBSs, at the eighth passage, either originating from the control or from the treated cells, CD133 increased twofold, whereas Oct4 increased by 40 and 85% in untreated and treated NBSs, respectively (Figure 1d ).
Since the effects on cell viability and clonogenicity, induced by 100 mM etoposide, were comparable to that induced by the higher doses, the subsequent analyses were performed until 100 mM.
At 24 h of treatment of cells with etoposide (10-100 mM) induced a dose-dependent increase of apoptotic cells and a necrotic effect was observed at 50 and 100 mM etoposide.
Etoposide produced a dose-dependent increase in dichlorofluorescein (DCF)-positive cells that became fivefold higher at 100 mM, and g-H2AX, a marker of DNA double-strand breaks, was induced in etoposide-treated cells (data not shown).
Etoposide activates p38MAPK, AKT and JNK. As shown in Figure 2a , 24-h etoposide increased protein kinase C (PKC)d and reduced PKCa levels. By analyzing the downstream molecular pathways of PKC, etoposide induced a dose-dependent activation of p38MAPK, already at 1.25 mM (Figure 2b, left panel) . In addition, c-Jun N-terminal kinase (JNK) was activated by 60 and 30%, at 1.25 and 10 mM, respectively, but no effect was observed at the other concentrations ( Figure 2b , right panel). Moreover, etoposide increased the activity of Akt (phospho-Thr-Akt/Akt) by 70% in cells treated with the dose of 1.25 mM and by 50 and 35% (phospho-Ser-Akt/Akt), respectively, in cells exposed to 50 and 100 mM (Figure 2b , lower panel).
SB203580/etoposide cotreatment decreases cell viability, reduces the clonogenicity and inhibits the formation of NBSs. Since all signaling molecules analyzed were already activated at 1.25 mM etoposide, the effects of specific enzymatic inhibitors were investigated at this concentration of etoposide. As shown in Figure 3a (left panel), a reduction of cell viability was observed when etoposide-treated cells were pre-exposed to LY290042 (phosphatidylinositol 3-kinase (PI-3-kinase)/Akt inhibitor; 15% decrease), to SB203580 (p38MAPK inhibitor; 17% decrease) and to SP600125 (JNK inhibitor; 30% decrease). As shown in Figure 3a (right panel), while PD98059 (MEK inhibitor) pretreatment increased the ability of NB cells to form colonies in the presence of etoposide, surprisingly, pre-treatment with SB203580 markedly reduced the tumorigenicity of etoposidetreated cells (60% decrease).
Treatment with the inhibitors that affected cell viability and tumorigenicity did not alter per se the number of NBSs (data not shown). As shown in Figure 3b , etoposide did not modify the number of NBSs, even in the presence of pre-treatment with LY290042 or SP600125 (first passage). However, when cells were pre-treated with SB203580 and then exposed to etoposide, the formation of NBSs was totally absent, even from the first passage (Figure 3b ).
In addition, the progressive increase in NBSs observed in untreated, etoposide-and cotreated cells was dependent on passages and lasted for a period of 5 weeks (Figure 3b ). After 6 weeks, the cotreatments did not change the number of NBSs (Figure 3b ).
In the NBSs originating from untreated and etoposidetreated cells, p38MAPK was activated 18-fold compared with monolayer cells (Figure 3c , left panel), whereas the expression of MAPK phosphatase-1 (MKP-1), p38MAPK inhibitor, did not change (Figure 3c , right panel). SB203580/etoposide or SP600125/etoposide cotreatments inhibit the formation of capillary-like structures. The ability of NB cells to form a network of tubes was not modified by etoposide or LY290042 after 24 h treatment (Figure 4a ). Instead, SB203580 and SP600125 alone decreased the number of branches in the tube network by 55% with regard to untreated cells (Figure 4a, graph) .
While the association of LY290042 with etoposide did not alter the formation of tubes, the cotreatment with SB203580 or SP600125 decreased the number of branches by 90% with regard to etoposide-treated cells (Figure 4a, graph) . Moreover, tubes formed by untreated, etoposide-or LY290042-treated and cotreated cells persisted for up to 3 days. Similar results were observed in cells incubated in medium without basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) (data not shown). Similarly, cotreatments of etoposide with LY290042 or SP600125 did not affect the cell migration (data not shown). It is worth noting that pre-treatment with SB203580 was able to reduce cell migration by 65% and 50%, evaluated by the scratch and Transwell assays, respectively ( Figure 4c ).
Cell invasion was reduced by 33% after etoposide treatment and was further inhibited by 51% and 80% after LY290042 and SB203580 cotreatments, respectively ( Figure 4d ). Moreover, SP600125 cotreatment did not change the number of membrane-invading cells (Figure 4d ). LY290042 or SB203580 alone reduced the cell invasion by 34% and 60%, respectively, while SP600125 per se was uneffective (data not shown).
Considering the effects induced by SB203580 cotreatment on cell migration and invasion, some molecular markers, known to be related to the invasive phenotype, were investigated.
As shown in Figure 5a , etoposide induced a 60% increase in the cyclooxygenase (COX)-2 levels, an effect that was totally inhibited by the pre-treatment with SB203580. Moreover, treatment with SB203580 alone did not modify the COX-2 levels in untreated cells (Figure 5a ).
Intercellular adhesion molecule-1 (ICAM-1) was reduced by 25% after etoposide and by 65% after SB203580 alone with regard to untreated cells (Figure 5b ). Moreover, SB203580 cotreatment reduced the ICAM-1 levels found after etoposide by 40% (Figure 5b ). As shown in Figure 5c , etoposide or SB203580 alone did not alter the C-X-C chemokine receptor-4 (CXCR4) levels, while cotreatment was able to decrease the CXCR4 by 60%.
Analyses of matrix metalloprotease (MMP) activity demonstrated that MMP-9 was secreted by untreated cells (Figure 5d ). In addition, etoposide or SB203580 alone did not influence the MMP-9 secretion (Figure 5d ). However, However, while the IMR-32 cell response to etoposide treatment was similar to that of HTLA-230 cells, SK-N-SH cells were more sensitive to the drug. In fact, 24-h etoposide, already at 1.25 mM, induced a reduction (of 30%) in cell viability of SK-N-SH (Figure 6a ). In addition, as shown in Figure 6b , the pretreatment of SK-N-SH with SB203580 caused a reduction of cell viability of 50% in regard to etoposide-treated cells, and sensitized IMR-32 cells, resistant to etoposide, by inducing a decrease of 48% in cell viability.
As shown in Figure 6c , etoposide alone decreased the number of colonies by 60% and 90% in SK-N-SH and IMR-32 cells, respectively. Moreover, in IMR-32 cells, SB203580 alone affected clonogenicity by reducing the clogenicity by 35% (Figure 6c ). In both cell lines, the pre-treatment with SB203580 further reduced the tumorigenicity induced by etoposide (Figure 6c) .
Untreated SK-N-SH and IMR-32 cells generated NBSs already within 1 week, and for each passage, the number of NBSs was equal to 30% of that originating from HTLA-230 (data not shown).
Etoposide or SB203580 alone totally inhibited the formation of NBSs in SK-N-SH but did not alter the number of NBSs in IMR-32 (data not shown). However, when IMR-32 cells were cotreated with SB203580 and etoposide, the formation of NBSs was totally prevented, even from the first passage (data not shown). As shown in Figure 6d , untreated and etoposidetreated monolayer SK-N-SH and IMR-32 cells expressed CD133 and Oct4 stem markers. Moreover, in NBSs, at the eighth passage, CD133 was markedly decreased (80-90%), whereas Oct4 did not change (Figure 6d) .
In NBSs, originating from SK-N-SH and IMR-32 untreated cells, an activation of p38MAPK 7-and 11-fold, respectively, 
Discussion
In this paper, we demonstrate that HTLA-230 and IMR-32, both MYCN-amplified cells, are highly etoposide-resistant, as only the doses ranging from 10 to 225 mM are able to reduce cell survival. In addition, HTLA-230 are more resistant than IMR-32 because 1.25 mM etoposide, a concentration that in vitro mimics the dose used in clinical therapy, 13 exerts a less marked antitumorigenic effect on HTLA-230, whereas the same dose of etoposide strongly decreases the clonogenicity of IMR-32 cells.
However, all NB cells analyzed are able to generate NBSs, but only in cells with MYCN-amplification, the treatment with etoposide does not interfere with NBS formation. These results are in agreement with a paper demonstrating that NBS-derived cells, originating from pediatric brain tumors, have an increased resistance to etoposide compared with monolayer-derived cells. 16 In addition, it has been demonstrated that only NB stage-IV-derived cells generate spheres, but that the MYCN expression status is not related to the sphere formation. 17 In this paper, we demonstrate that in NBSs, originating from HTLA-230 cells, the levels of stemness markers (CD133 and Oct4) are enhanced, while in NBSs, originating from SK-N-SH and IMR-32 cells, the expression of CD133 is reduced and Oct4 do not change. These results are in line with a report demonstrating that CD133 expression is increased in spheres but not in every analyzed sphere derived from NB samples and cell lines. 17, 18 Probably, the overexpression of stemness markers contributes to rendering HTLA-230 more resistant to etoposide, and in this regard, it has been demonstrated that CD133 expression in NB cells is associated with resistance to doxorubicin, vincristine and cisplatin. 19 In accordance with other studies, 20 we have recently reported that etoposide causes DNA damage and an overproduction of reactive oxygen species (ROS), 21 which have been demonstrated to mediate both cell damage and biological functions. 22 In this regard, herein we show that etoposide induces a dose-dependent increase in the levels of the proapoptotic PKCd 23 and a parallel decrease of PKCa, the antiapoptotic isoform. 24 However, given that PKCs are upstream molecules in the ROS signaling pathway leading to DNA damage and apoptosis, 21, 25, 26 it is important to identify the downstream mediators of the NB response to etoposide and we show that etoposide induces the activation of Akt and MAPKs (i.e. JNK, and p38). It is worth noting that the activation of MAPKs has been reported in over 50% of acute myelogenous and lymphocytic leukemia and that MAPKs are also stimulated in other tumors, 27, 28 therefore implying that the inhibition of the MAPK pathways could represent an important strategy to counteract tumor growth. In this context, our results demonstrate that the viability of HTLA-230 exposed to 1.25 mM etoposide is reduced by the cotreatment with MAPKs and Akt inhibitors.
Moreover, cotreatment with etoposide and SB203580, a specific p38MAPK inhibitor, markedly reduces the tumorigenicity, while PD98059, an inhibitor of MEK, increases the ability to form colonies. These findings are in line with studies demonstrating, on the one hand, that p38MAPK activation plays a key role in tumorigenicity 29 and, on the other hand, that PD98059 fails to reduce the toxicity of etoposide. 30 For the first time, we have demonstrated that SB203580, synergizing with etoposide, totally inhibits the formation of NBSs. This is probably related to the evidence that NBSs originating from MYCN-amplified cells have higher levels of p38MAPK activity in comparison to the same cells grown in monolayer and to NBSs originating from MYCN non-amplified cells. To confirm the fundamental role played by p38MAPK activation in CSC generation and propagation, the role of MKP-1, an endogenous inhibitor of MAPKs, 31 was investigated with the result that, in NBS cells, no changes were observed in MKP-1. Recently, it has also been demonstrated that p38MAPK activity enhances the expression of a specific subset of Oct4 target genes. 32 In this regard, SB203580 plus etoposide does not allow the formation of NBSs, probably due to its acting on CD133 and Oct4. Moreover, it has been found that CD133-positive cells maintain self-renewal and CSC-like properties by involving Oct4, 15 whose transcript is detected in many human carcinomas, 33 including NB.
11
Noteworthy is that our data confirm previous evidence indicating that the p38 kinase is involved in the production of VEGF 34 and in VEGF-induced endothelial migration. 35 An additional mechanism of tumor angiogenesis is represented The p38MAPK pathway is known to regulate cancer development by modulating not only angiogenesis but also cell motility and invasion. In this context, our results demonstrate that migration and invasiveness of etoposidetreated NB cells is dependent on p38MAPK and also suggest that the inhibition of this pathway could be a new strategy in limiting the invasiveness of stage-IV NB. Accordingly, it has been demonstrated that SB203580 negatively affects, in vivo, breast cancer cell invasiveness, 38 whereas in vitro studies show that migration and invasion of bladder and hepatocarcinoma cells are linked to p38MAPK activity. 39, 40 Growing evidence also demonstrates that CXCR4, the chemokine stromal-derived factor 1 (SDF1/CXCL12) receptor, plays a key role in NB biology 41 and exerts a promigratory effect by activating p38MAPK. 42 Another modulator of the cancer invasiveness, whose expression is associated with the activation of MAPKs, is COX-2, (ref. [43] [44] [45] which increases migration and modulates the expression of the ICAM-1, an inducible surface glycoprotein that mediates adhesiondependent cell-to-cell interactions. 46 In this regard, we have demonstrated that in HTLA-230 cells, etoposide markedly increases COX-2 expression according to the evidence that chemo/radiotherapies induce COX-2 in cancer. 47 On the other hand, etoposide reduces ICAM-1 and, although it does not affect cell survival, markedly reduces the cell invasiveness.
Probably, the effect of etoposide is the result of a balance between the increased expression of COX-2, linked to a major survival and migratory ability, and the reduced ICAM-1 expression, leading to a reduction of the metastatic potential of tumor cells. The cotreatment of etoposide with SB203580, by downregulating the expression of both proteins, on the one hand, determines a cytotoxic and antiangiogenetic effect and, on the other hand, reduces the invasive and metastatic properties. The demonstration that p38MAPK may regulate NB cell migration and invasiveness is confirmed by the inhibitory effect of SB203580 on the MMP-9 activity. Therefore, these results strongly suggest that the combination of etoposide with SB203580 might be effective in blocking tumor growth and metastases.
Some preclinical studies have demonstrated that SB203580 is pharmacologically active in vivo in several animal models and is a potent inhibitor of cytokine production with only minor effects on the immune system. 48 Several p38 inhibitors tested for the treatment of inflammatory diseases have been well tolerated with minimal side effects. 49 Of particular note, there is increasing evidence that the different proinflammatory chemokines are implicated in the growth and invasivity of NB. 50 In conclusion, we believe that, due to the dual activity on cancer cells and tumor microenvironment, standard chemotherapy combined with p38 inhibitors could represent a successful therapeutic strategy for the treatment of stage-IV NB. . The cell line was tested for mycoplasma contamination (Mycoplasma Reagent Set; Euroclone s.p.a, Pavia, Italy). Cell morphology and proliferation were analyzed after thawing and within eight passages in culture. Cells were cultured in RPMI1640 (Euroclone) supplemented with 10% fetal bovine serum (FBS; Euroclone), 2 mM glutamine (Euroclone), 1% penicillin/streptomycin (Euroclone), 1% sodium pyruvate (Sigma) and 1% of amino-acid solution (Sigma). Cells were treated for 24 h with etoposide doses ranging from 0.07 to 225 mM, and then, in a series of experiments, were pre-treated for 1 h with various enzymatic inhibitors of different signaling pathways: 0.1 mM chelerythrine chloride (PKC, pan inhibitor), 500 nM LY290042 (PI-3-kinase/Akt inhibitor), 50 mM PD98059 (MAP kinase kinase, MEK, inhibitor), 10 mM SB203580 (p38MAPK inhibitor) or 4 mM SP600125 (JNK inhibitor).
The stock solutions of etoposide and chemical inhibitors were prepared in DMSO and pilot experiments have demonstrated that the final DMSO concentrations did not change the cell responses analyzed.
MTT assay. Cell viability was determined using the dimethylthiazolyl-2-5-diphenyltetrazolium bromide (MTT; Sigma) staining. Briefly, cells were seeded into 96-well plates (Corning Incorporated, Corning, NY, USA) and then treated with etoposide and/or inhibitors for 24 h. Next, the cells were incubated with 0.5 mg/ml MTT for 3 h at 37 1C. After incubation, the supernatant was discarded, insoluble formazan precipitates were dissolved in HCl (0.1 N in isopropanol) and the absorbance at 570 nm was recorded using a microplate reader (EL-808; BioTek Instruments Inc., Winooski, VT, USA). Clonogenic assay. NB cells (150 per well) were seeded in six-well plates (Corning) and treated with etoposide and/or inhibitors for 24 h. Subsequently, the medium was changed and the cells were maintained in drug-free medium for 20 days. Cells were then fixed with methanol and stained with crystal violet (0.5% in water with 50% methanol). Colonies containing more than 50 cells were counted and the images were acquired with a Nikon Coolpix L22 camera (Nikon Corporation, Tokyo, Japan).
Soft-agar colony formation assay. NB cells were plated into six-well plates in the presence or absence of etoposide and/or inhibitors for 24 h. Anchorage-independent growth was carried out as follows: base agar (0.5% agar, RPMI1640 and 10% FBS) was added to each well and allowed to solidify, and then an equal volume of top agar (0.35% agar, RPMI1640 and 10% FBS), containing untreated or treated cells (10 3 cells per cm 2 ), was added to each well. Plates were incubated in a 5% CO 2 humidified incubator at 37 1C for 25 days. Colonies were stained with 0.005% crystal violet. Colonies containing more than 25 cells were counted by a Leica DMIRB microscope (Leica, Wetzlar, Germany) and the images were acquired with a Nikon Coolpix L22 camera (Nikon).
Sphere culture of NB cells. After treatment, NB cells were cultured in DMEM-F12 knockout medium (Invitrogen, Paisley, UK) containing 1% penicillin/ streptomycin (Euroclone), 2% B27 supplement (Invitrogen), 40 ng/ml bFGF (R&D Systems Inc., Minneapolis, MN, USA) and 20 ng/ml epidermal growth factor (EGF; Invitrogen). 51 Half of the medium was then replaced with fresh culture medium every 7 days.
The self-renewal capacity of NBSs was determined by counting the spheres in the liquid culture. Growth curves were established by mechanically dissociating the passaged tumor spheres, plating 16 Â 10 4 single cells in 25 cm 2 flasks and assessing the NBSs number at every passage.
RT-PCR analysis. Total RNA was extracted using TRIZOL reagent (Invitrogen) according to the manufacturer's instructions. Total RNA (1 mg) was reversetranscribed into cDNA by random hexamer primer and SuperScript II Reverse Transcriptase (Invitrogen).
Amplification of cDNA by a polymerase chain reaction was performed using AmpliTaq Polymerase (Invitrogen) and specific primers for CD133, Oct4 and GAPDH. Primer sequences were: CD133 Fw - Fluorescence microscopy analysis of apoptotic and necrotic cells. For the assessment of apoptosis and necrosis, cells were analyzed as described previously. 25 Following treatment, cells were incubated with 0.5 mg/ml fluorescein isothiocyanate (FITC)-labeled recombinant Annexin-V and 0.5 mg/ml propidium iodide (PI; BioVision, Mountain View, CA, USA). Cells were then visualized and counted (four fields of 200-400 cells) by fluorescence microscopy using a Leica DMIRB microscope (Leica) with a dual filter set for FITC and rhodamine. Images were acquired with a Leica DCF320 camera. Cell death was evaluated as a percentage of Annexin-V (apoptotic) or PI-positive (necrotic) cells.
Detection of ROS production. Detection of ROS was performed as reported previously. 25 After treatment, cells were incubated with 20 mM 2 0 ,7 0 -dichlorofluorescein-diacetate (DCFH-DA; Sigma) and the accumulation of DCF was analyzed at 530/485 nm. The cells were then observed and counted (four fields of 200-400 cells) by fluorescence microscopy using a Leica DMIRB microscope with a standard set of filters for fluorescein. The images were acquired with a Leica DCF320 camera.
DNA damage. Cells were seeded on chamber slides (Iwaky Seiyaku Co., Tokyo, Japan) treated with etoposide, fixed with paraformaldehyde (4% in PBS pH 7.5) and permeabilized with Triton 0.1%.
Nonspecific antibody binding was blocked by a 30 min incubation with 1% BSA and 1% gelatine. Cells were treated with anti-g-H2AX antibody (1 : 500; Abcam, Cambridgeshire, UK) and then incubated with an FITC-conjugated anti-mouse antibody (Upstate, Lake Placid, NY, USA). Nuclei were identified by PI staining. Images were collected by fluorescence microscopy (Leica DMIRB microscope) with a dual filter set for FITC and rhodamine. The images were acquired with a Leica DCF320 camera.
Immunoblot analysis. Immunoblots were carried out according to standard methods 25 using monoclonal mouse antibodies, anti-PKCa (Upstate, Lake Placid, NY, USA), anti-b-actin (Sigma), anti-g-H2AX, anti-ICAM-1, anti-JNK (Abcam), anti-VEGF (Abnova, Taipei, Taiwan), and polyclonal rabbit antibodies, anti-human PKCd, anti-Akt, anti-phospho-Akt (Thr308), anti-phospho-Akt (Ser473), antip38MAPK, anti-phospho-p38MAPK (Cell Signalling Technology Inc., Danvers, MA, USA), anti-phospho-JNK (Thr183) and anti-phospho-JNK (Tyr185), anti-CXCR4, anti-COX2 (Abcam), anti-MKP-1 and anti-GAPDH (Sigma).
Anti-mouse and anti-rabbit secondary antibodies were coupled with horseradish peroxidase (Amersham International, Buckinghamshire, UK). Proteins were visualized with an enzyme-linked chemiluminescence detection kit according to the manufacturer's (Amersham) instructions. Chemiluminescence was monitored by exposure to film and the signals were analyzed under non-saturating conditions with an image densitometer connected to Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).
Formation of capillary-like structures. In vitro formation of capillary-like structures was carried out on untreated and treated HTLA-230 cells (2 Â 10 4 cells per well), seeded into a 96-Matrigel-coated well plate, adding endothelial basal medium in the presence or absence of VEGF (15 ng/ml) and bFGF (50 ng/ml). 11 In parallel, 10 mM sulforaphane was added as a control inhibitor of the capillary-like structure formation. Samples were analyzed over a 4-48 h period with a microscope (Leica DMIRB) using Â 10 and Â 20 lenses.
'Scratch' assay. HTLA-230 cells were plated into 24-well plates and cultured until confluent. A 200 ml pipette tip was used to 'scratch' the cell monolayers and then etoposide and/or inhibitors were added for 24 h. Photomicrographs were taken using an inverted microscope (Leica DMIRB) equipped with a Â 10 lens. To evaluate the cell migration rate, images were recorded at time 0 and 24 h after the treatments. The distance between the two margins of the wound was analyzed by Adobe Photoshop 7.0.1.
Migration assay. Cell migration assay was carried out using the Transwell system (Corning) equipped with 8-mm pore size polycarbonate filters. Cells (5 Â 10 4 ), suspended in serum-free medium, were plated into the upper chambers in the presence or absence of etoposide and/or inhibitors and allowed to migrate towards the lower chamber containing medium with 5% FBS, as a chemoattractant, for 24 h. Subsequently, the unmigrating cells in the upper compartment were removed using cotton swabs and the cells that had migrated to the lower surface of the filters were fixed with glutaraldehyde 2.5% (Sigma) and stained with Gill's hematoxylin no.1 solution (Sigma), following the manufacturer's instructions. The quantity of cells that had migrated through the filter was evaluated by microscopy analysis (Leica DMIRB microscope) using a Â 10 lens.
Invasion assay. In vitro invasion assay was carried out in BD BioCoat Matrigel Invasion Chambers (BD) with 8 mm pores into 24-well plates, following the manufacturer's instructions. Cells (5 Â 10 4 ), suspended in serum-free medium, were plated into the upper coated chambers in the presence or absence of etoposide and/or inhibitors and allowed to migrate towards the lower chamber containing medium with 5% FBS, as a chemoattractant, for 24 h. Subsequently, the unmigrated cells in the upper chamber were gently scraped off the filter. The quantity of cells that had migrated through the filter was evaluated by crystal violet staining and microscopy analysis (Leica DMIRB microscope) using a Â 10 lens.
MMP activity. MMP activity in the conditioned media was determined by zymography, according to the methods described by Bernhard and Muschel. 52 Cells were cultured and treated in serum-free medium. Subsequently, the conditioned medium was harvested and centrifuged at 14 000 r.p.m. Â 10 min at room temperature and the resulting supernatant was concentrated by using Amicon Ultra Centrifugal Filters (Millipore Ireland Ltd, Country Cork, UK). The total protein amount was determined by the BCA method (Pierce, Thermo Scientific, Rockford, IL, USA).
Substrate polyacrylamide gel electrophoresis was carried out by a modified protocol of Heussen and Dowdle, 53 using the gelatine Ready Gel Zymogram 10% (Bio-Rad Laboratories). Briefly, samples were mixed with Laemmli buffer (in a ratio of 3 : 1), warmed at 37 1C for 30 min and subjected to gel electrophoresis. Subsequently, the gel was incubated for 48 h in developing buffer (50 mM Tris (pH 7.4), 0.2 M NaCl, 1% Triton X-100, 0.02 sodium azide and 5 mM CaCl 2 ). After this step, the gel was stained for 1 h (0.2% Coomassie Blue, 30% ethanol and 10% acetic acid) and then de-stained in a solution containing 10% acetic acid. The gelatine digestion was analyzed with an image densitometer connected to Quantity One software (Bio-Rad Laboratories).
Data analysis. Results were expressed as mean±S.D. from at least three independent experiments. The statistical significance of parametric differences among sets of experimental data was evaluated by one-way ANOVA and Dunnett's test for multiple comparisons.
